Metraipolis › archive › dc_eec75892afef

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma — Europe PMC PMID:40861017

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40861017
DOI: 10.36469/001c.142403
License (as archived): solo-consultazione
Archived: 2026-11-10T11:00:13.080Z
SHA-256 of the archived text: 4f58c5decda128262953c8db923632419c4e9be4b09e0db022232e59eb65bc91
Stable URL of this page: https://metraipolis.com/documento/dc_eec75892afef

How to cite

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma — Europe PMC PMID:40861017 — Europe PMC (en), https://europepmc.org/article/MED/40861017 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eec75892afef (Metraipolis archive dc_eec75892afef, sha256 4f58c5decda128262953c8db923632419c4e9be4b09e0db022232e59eb65bc91)

BibTeX

@misc{dceec75892afef,
  title = {Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma — Europe PMC PMID:40861017},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40861017},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eec75892afef; sha256 4f58c5decda128262953c8db923632419c4e9be4b09e0db022232e59eb65bc91},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40861017. Agents can read the archived copy with the MCP tool read_document.